Futura Medical (GB:FUM) has released an update.
Futura Medical PLC, the healthcare company focused on sexual health products like Eroxon, has announced that CEO James Barder and Executive Head of R&D Ken James have exercised a significant number of options, resulting in changes to their holdings in the company. Barder has sold some shares to cover tax liabilities while retaining others, and both executives’ shareholdings now represent a small percentage of the company’s issued share capital. The company notes that any unexercised options will lapse by the end of the month, highlighting the company’s current total issued share capital and voting rights.
For further insights into GB:FUM stock, check out TipRanks’ Stock Analysis page.